title: Comparison of ¹⁸F-fluoride PET/CT, ¹⁸F-FDG PET/CT and bone scintigraphy (planar and SPECT) in detection of bone metastases of differentiated thyroid cancer: a pilot study.
abstract: OBJECTIVE
  We compared the efficacies of ¹⁸F-fluoride positron emission tomography (¹⁸F-fluoride PET)/CT, ¹⁸F-fludeoxyglucose PET (¹⁸F-FDG PET)/CT, and ⁹⁹mTc bone scintigraphy [planar and single photon emission CT (SPECT)] for the detection of bone metastases in patients with differentiated thyroid carcinoma (DTC).
  
  
  METHODS
  We examined 11 patients (8 females and 3 males; mean age 6 standard deviation, 61.968.7 years) with DTC who had been suspected of having bone metastases after total thyroidectomy and were hospitalized to be given ¹³¹I therapy. Bone metastases were verified either when positive findings were obtained on both ¹³¹I scintigraphy and CT or when MRI findings were positive if MRI was performed.
  
  
  RESULTS
  Metastases were confirmed in 24 (13.6%) of 176 bone segments in 9 (81.8%) of the 11 patients. The sensitivities of ¹⁸F-fluoride PET/CT and ⁹⁹mTc bone scintigraphy (SPECT) were significantly higher than those of ¹⁸F-FDG PET/CT and ⁹⁹mTc bone scintigraphy (planar) (p,0.05). The accuracies of ¹⁸F-fluoride PET/CT and mTc bone scintigraphy (SPECT) were significantly higher than that of ⁹⁹mTc bone scintigraphy (planar) (p,0.05).
  
  
  CONCLUSIONS
  The sensitivity and accuracy of ¹⁸F-fluoride PET/CT for the detection of bone metastases of DTC are significantly higher than those of ⁹⁹mTc bone scintigraphy (planar). However, the sensitivity and accuracy of ⁹⁹mTc bone scintigraphy (planar) are improved near to those of ¹⁸F-fluoride PET/CT when SPECT is added to a planar scan. The sensitivity of ¹⁸F-FDG PET/CT is significantly lower than that of 18F-fluoride PET/CT or ⁹⁹mTc bone scintigraphy (SPECT).
authors.forename: Naotoshi
authors.initials: N
authors.lastname: Ota
authors.forename: Katsuhiko
authors.initials: K
authors.lastname: Kato
authors.forename: Shingo
authors.initials: S
authors.lastname: Iwano
authors.forename: Shinji
authors.initials: S
authors.lastname: Ito
authors.forename: Shinji
authors.initials: S
authors.lastname: Abe
authors.forename: Naotoshi
authors.initials: N
authors.lastname: Fujita
authors.forename: Keiichi
authors.initials: K
authors.lastname: Yamashiro
authors.forename: Seichi
authors.initials: S
authors.lastname: Yamamoto
authors.forename: Shinji
authors.initials: S
authors.lastname: Naganawa
mesh_terms: D018263:Adenocarcinoma, Follicular / Q000175:diagnosis* / Q000556:secondary* / Q000601:surgery; D000368:Aged; D001859:Bone Neoplasms / Q000175:diagnosis* / Q000556:secondary*; D001842:Bone and Bones / Q000000981:diagnostic imaging; D002291:Carcinoma, Papillary / Q000175:diagnosis* / Q000556:secondary* / Q000601:surgery; D003937:Diagnosis, Differential; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D010865:Pilot Projects; D049268:Positron-Emission Tomography / Q000379:methods; D012680:Sensitivity and Specificity; D013964:Thyroid Neoplasms / Q000601:surgery; D013965:Thyroidectomy; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed / Q000379:methods
chemical_list: D019788:Fluorodeoxyglucose F18